A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen

摘要: Purpose: In the adjuvant treatment of estrogen receptor (ER)–positive breast cancer, additional markers are needed to identify women at high risk for recurrence. Experimental Design: We examined association between ratio homeobox 13 (HOXB13) interleukin-17B (IL-17BR) expression and clinical outcomes relapse survival in with ER-positive cancer enrolled onto a North Central Cancer Treatment Group tamoxifen trial (NCCTG 89-30-52). Results: Tumor blocks were obtained from 211 256 eligible patients, quantitative reverse transcription-PCR profiles HOXB13 IL-17BR 206 patients. The cut point two-gene log 2(expression ratio) that best discriminated outcome (recurrence survival) was selected identified significantly worse relapse-free (RFS), disease-free (DFS), overall (OS), independent standard prognostic markers. differed as function nodal status [node negative (59th percentile) versus node positive (90th percentile)]. node-positive cohort ( n = 86), HOXB13/IL-17BR not associated or survival. contrast, node-negative 130), RFS [hazard (HR), 1.98; P 0.031], DFS (HR, 2.03; 0.015), OS 2.4; 0.014), Conclusion: A is increased death patients resected node-negative, treated may whom alternative therapies should be studied.